Aurora Cannabis Record International Medical Revenue – Quarterly Update Report
Aurora Cannabis (ACB) reported record international medical revenue of C$61.4M, up 44% y/y, driving 2Q FY27 revenue to C$86.0M. Adjusted EBITDA improved to C$14.0M. ACB agreed to be acquired by Organigram for C$7.80/share, a 93% premium, valuing it at C$561M. ACB shareholders will retain ~35% ownership. The deal aims to create a global cannabis leader with expanded international reach and manufacturing scale.
How this was made
The 30-second read
Why it matters
If approved, the combined entity will control ~35% of the new platform, offering cross‑selling opportunities and cost synergies.
Market read
The deal is a material M&A event in the cannabis sector, likely moving both ACB and OGI stocks.
What to watch
Regulatory approvals in Europe and potential competition from Curaleaf may limit upside.
Background
The acquisition follows a competing Curaleaf proposal and reflects ongoing consolidation in the cannabis industry.
Ticker impact
Aurora Cannabis (ACB) announced a C$7.80 per share acquisition by Organigram, a 93% premium valuing ACB at C$561 million.
likely upside as market prices in the premium and synergy potential
Premium valuation and synergies are material; investors typically reward such M&A announcements.
Market effects
Consolidation may raise competitive barriers in the global medical cannabis sector.
European and Canadian cannabis markets could see tighter supply dynamics.
Creates a larger player that may attract institutional interest worldwide.
Counterpoint
The deal could overpay for ACB, leading to integration challenges and share dilution.
Key entities
- companyAurora Cannabis
Target of the acquisition, Canadian medical cannabis producer.
- companyOrganigram
Acquirer, Canadian cannabis company expanding internationally.
- investorBAT
Major shareholder providing financing and equity investment.
